Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 11, 2015 - Issue 9
Submit an article Journal homepage
491
Views
6
CrossRef citations to date
0
Altmetric
Drug Profile

Adalimumab for the treatment of pediatric Crohn’s disease

Federica NutiPediatric Unit, Vimercate Hospital, Vimercate, ItalyCorrespondence[email protected]
,
Gionata FiorinoIBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Italy
&
Silvio DaneseIBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Italy
Pages 963-972 | Published online: 27 Jul 2015

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Anthony Mark Dalzell & Muhammad Eyad Ba’Ath. (2019) Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries. Paediatrics and International Child Health 39:1, pages 48-58.
Read now

Articles from other publishers (5)

Yenan Fang, Bingyan Shen, Qin Dai, Qiqi Xie, Wencan Wu & Min Wang. (2023) Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment. European Journal of Medical Research 28:1.
Crossref
Jamel Corredores, Brice Vofo & Radgonde Amer. (2023) Uveitis in Children: The Role of Biological Agents in Its Management. Biomedicines 11:2, pages 629.
Crossref
Alyson Yamaguchi, Jacques Van Dam, Arvinder K. Dhalla, Kyle Horlen, Mir Imran, April T. Vo & Mir A. Hashim. (2022) Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines. Frontiers in Drug Delivery 2.
Crossref
Víctor Manuel Navas-López, Gemma Pujol Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas & Javier Martin-de-Carpi. (2018) Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn. Anales de Pediatría 88:2, pages 89-99.
Crossref
Víctor Manuel Navas-López, Gemma Pujol-Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas & Javier Martin-de-Carpi. (2018) A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease. Anales de Pediatría (English Edition) 88:2, pages 89-99.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.